These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17333159)

  • 1. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
    Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
    Tornio A; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.
    Backman JT; Honkalammi J; Neuvonen M; Kurkinen KJ; Tornio A; Niemi M; Neuvonen PJ
    Drug Metab Dispos; 2009 Dec; 37(12):2359-66. PubMed ID: 19773535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
    Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
    Niemi M; Tornio A; Pasanen MK; Fredrikson H; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Jun; 62(6):463-72. PubMed ID: 16758263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
    Niemi M; Backman JT; Juntti-Patinen L; Neuvonen M; Neuvonen PJ
    Br J Clin Pharmacol; 2005 Aug; 60(2):208-17. PubMed ID: 16042675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
    López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
    Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast.
    Karonen T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2011 Feb; 67(2):151-5. PubMed ID: 20931329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.
    Karonen T; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2012 Feb; 73(2):257-67. PubMed ID: 21838784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.
    Aquilante CL; Kosmiski LA; Bourne DW; Bushman LR; Daily EB; Hammond KP; Hopley CW; Kadam RS; Kanack AT; Kompella UB; Le M; Predhomme JA; Rower JE; Sidhom MS
    Br J Clin Pharmacol; 2013 Jan; 75(1):217-26. PubMed ID: 22625877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
    Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2012 May; 91(5):846-55. PubMed ID: 22472994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
    Niemi M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2001 Nov; 70(5):439-45. PubMed ID: 11719730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
    Niemi M; Backman JT; Granfors M; Laitila J; Neuvonen M; Neuvonen PJ
    Diabetologia; 2003 Oct; 46(10):1319-23. PubMed ID: 12898007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.
    Filppula AM; Tornio A; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2013 Sep; 94(3):383-93. PubMed ID: 23657159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
    Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
    Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2008 Sep; 84(3):403-11. PubMed ID: 18388877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans.
    Honkalammi J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2011 Apr; 89(4):579-86. PubMed ID: 21368757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.